These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 19072367)

  • 21. Review article: interactions between genotype and response to therapy in inflammatory bowel diseases.
    Herrlinger KR; Jewell DP
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1403-12. PubMed ID: 17081161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic approaches in inflammatory bowel disease based on the immunopathogenesis.
    Siegmund B; Zeitz M
    Rocz Akad Med Bialymst; 2004; 49():22-30. PubMed ID: 15631310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.
    Sparrow MP; Hande SA; Friedman S; Lim WC; Reddy SI; Cao D; Hanauer SB
    Aliment Pharmacol Ther; 2005 Sep; 22(5):441-6. PubMed ID: 16128682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents.
    Kwon JH; Farrell RJ
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):169-78. PubMed ID: 15979323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease.
    Mossop H; Davies P; Murphy MS
    J Pediatr Gastroenterol Nutr; 2008 Aug; 47(2):123-9. PubMed ID: 18664861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review article: thiopurines in inflammatory bowel disease.
    Derijks LJ; Gilissen LP; Hooymans PM; Hommes DW
    Aliment Pharmacol Ther; 2006 Sep; 24(5):715-29. PubMed ID: 16918876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.
    Sparrow MP; Hande SA; Friedman S; Cao D; Hanauer SB
    Clin Gastroenterol Hepatol; 2007 Feb; 5(2):209-14. PubMed ID: 17296529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.
    de Boer NKH; Peyrin-Biroulet L; Jharap B; Sanderson JD; Meijer B; Atreya I; Barclay ML; Colombel JF; Lopez A; Beaugerie L; Marinaki AM; van Bodegraven AA; Neurath MF
    J Crohns Colitis; 2018 Apr; 12(5):610-620. PubMed ID: 29293971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Use of immunosuppressors in chronic inflammatory intestinal diseases].
    Lémann M
    Gastroenterol Clin Biol; 1999 Jun; 23(5 Pt 2):B178-88. PubMed ID: 10897790
    [No Abstract]   [Full Text] [Related]  

  • 30. Evidence for a functional genetic polymorphism of the Rho-GTPase Rac1. Implication in azathioprine response?
    Bourgine J; Garat A; Allorge D; Crunelle-Thibaut A; Lo-Guidice JM; Colombel JF; Broly F; Billaut-Laden I
    Pharmacogenet Genomics; 2011 Jun; 21(6):313-24. PubMed ID: 21372752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chronic inflammatory bowel diseases. Immunosuppressive drug saves on corticoids].
    MMW Fortschr Med; 1999 Sep; 141(38):55. PubMed ID: 10904620
    [No Abstract]   [Full Text] [Related]  

  • 32. Medical therapy of IBD in 2009.
    Harris A; Feller ER; Shah SA
    Med Health R I; 2009 Mar; 92(3):78-81. PubMed ID: 19385382
    [No Abstract]   [Full Text] [Related]  

  • 33. Review article: practical management of inflammatory bowel disease patients taking immunomodulators.
    Siegel CA; Sands BE
    Aliment Pharmacol Ther; 2005 Jul; 22(1):1-16. PubMed ID: 15963074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Benefits and risks of immunosuppression in chronic inflammatory bowel diseases].
    Rogler G
    Dtsch Med Wochenschr; 2008 Sep; 133(38):1917-21. PubMed ID: 18785084
    [No Abstract]   [Full Text] [Related]  

  • 35. Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome.
    Shah JA; Edwards CM; Probert CS
    Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):169-73. PubMed ID: 18301295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are we ready for top-down therapy for inflammatory bowel diseases: con.
    Herfarth H
    Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):249-55. PubMed ID: 19072417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Azathioprine side effects in the treatment of chronic inflammatory bowel disease.
    González Lara V; Pérez Calle JL
    Rev Esp Enferm Dig; 2001 Dec; 93(12):765-8. PubMed ID: 11995358
    [No Abstract]   [Full Text] [Related]  

  • 38. A history of immunosuppressive drugs in the treatment of inflammatory bowel disease: origins at the Mount Sinai Hospital.
    Korelitz BI; Present DH
    Mt Sinai J Med; 1996; 63(3-4):191-201. PubMed ID: 8692165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing the therapeutic potential of azathioprine/6-mercaptopurine in the treatment of inflammatory bowel disease.
    Papadakis KA
    J Clin Gastroenterol; 2003; 36(5):379-81. PubMed ID: 12702974
    [No Abstract]   [Full Text] [Related]  

  • 40. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine.
    Nielsen OH; Vainer B; Rask-Madsen J
    Aliment Pharmacol Ther; 2001 Nov; 15(11):1699-708. PubMed ID: 11683683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.